We are Juno –
an Australian team of innovative thinkers,
passionate about supporting hospitals and
healthcare specialists with industry leading,
off-patent pharmaceuticals.

Company NEWS

Juno Pharmaceuticals appointed as Fresenius Kabi’s exclusive distribution partner for IDACIO® (adalimumab)

We are pleased to announce that Fresenius Kabi Australia Pty Limited (Fresenius Kabi) has appointed Juno Pharmaceuticals (Juno) as their exclusive distribution partner for IDACIO® (adalimumab) (rch) 40 mg solution for injection pre-filled pen & pre-filled syringe. Read more

product NEWS

Juno Pharmaceuticals Acquires Noradrenaline 2 mg/2 mL & 4 mg/4 mL from Mayne Pharma

MELBOURNE, AUSTRALIA – Juno Pharmaceuticals is pleased to announce the acquisition of noradrenaline 2 mg/2 mL and 4 mg/4 mL concentrated injection from Mayne Pharma; an important addition to Juno’s growing range of vasopressors and critical care medicines. Read more

Our Products

Know what product you're looking for or need help with your search? Just use the search function below to find it by product name or category.

OR

Partnering with Juno

Working with the right partners is key for us. It means that we can deliver our products as quickly and efficiently as possible to hospitals and healthcare specialists.

For our partners, it’s our competitive edge as a privately owned Australian business, our understanding of the Australian and New Zealand hospital markets, our collaborative outlook and innovative approach that sets us apart.

Learn more